If you are running a disease-modifying CNS or neurodegeneration trial, the imaging decision comes down to one question: who can deliver a reproducible, submission-ready biomarker endpoint across every site? QMENTA is built for that outcome. Quibim is built for a different one: organ-specific AI diagnostics deployed inside hospital radiology departments. Both use cloud-based AI to generate quantitative imaging biomarkers, but they serve different buyers and different jobs. This comparison is written for the trial sponsors and CROs weighing the two.
QMENTA is the biomarker measurement partner for disease-modifying CNS and neurodegeneration trials. Sponsors rely on QMENTA to turn multi-site scans into reproducible, submission-ready endpoints. These are the atrophy, lesion, and tract measurements that move a trial’s primary outcome, delivered without the site-to-site variability that undermines a multi-center imaging dataset. Founded in 2013, QMENTA has concentrated that work on the neuroimaging endpoints disease-modifying trials depend on.
A key differentiator for QMENTA is its Imaging Biomarker Marketplace, which hosts over 50 validated algorithms. This allows sponsors to deploy not only QMENTA’s proprietary tools but also industry-standard third-party algorithms (like FSL or FreeSurfer). But the defensible value is the layer QMENTA owns: the automated QC, sequence harmonization, and regulatory-grade validation that make those measurements trustworthy and reproducible across sites, all inside a 21 CFR Part 11-compliant environment.
QMENTA defined: .the partner that delivers a trustworthy, reproducible CNS imaging endpoint for your trial. Organizations centralize multi-site data on it, validate AI biomarkers in a regulated environment, manage central review, and generate submission-ready outputs, all within a single compliant infrastructure designed specifically for drug development.
Quibim (Quantitative Imaging Biomarkers in Medicine) is a Spanish health technology company specializing in organ-specific AI diagnostics for hospital radiology. Founded in 2015, it closed a $50 million Series A in January 2025.
Quibim’s approach is product-first: cleared, organ-specific diagnostic tools for prostate, brain, and liver that plug into a hospital’s existing radiology workflow. Its commercial value lies in these specialized, biopsy-validated diagnostic products, with QP-Insights® serving as a data layer that links imaging with EHR and genomic data for patient stratification. This makes Quibim a strong fit for radiology departments and precision-medicine programs - a different job than producing a regulated multi-site trial endpoint.
QMENTA as the trial endpoint partner: QMENTA’s job is to deliver one thing well. It provides a reproducible imaging biomarker endpoint a sponsor can submit to a regulator. It harmonizes multi-site data and validates the measurement so the number means the same thing at every site. That is the difference between an imaging dataset and a defensible trial endpoint, and it is why neuro-focused sponsors and CROs choose QMENTA.
Quibim as Hospital Diagnostic Specialist: Quibim provides cleared, organ-specific diagnostic tools (such as QP-Prostate®) that embed in hospital radiology workflows. This model is ideal for teams seeking deep, proprietary analysis within a specific therapeutic area like oncology or metabolic liver disease.
Practical implications: Organizations whose primary challenge is executing a regulated, multi-site imaging trial with complex QC, harmonization, and audit trail requirements tend to prioritize QMENTA's end-to-end trial infrastructure. If your primary challenge is embedding organ-specific diagnostic reads into hospital radiology, Quibim’s cleared devices fit that workflow directly.
| Feature | QMENTA | Quibim |
|---|---|---|
| Primary Philosophy | Deliver a reproducible CNS trial endpoint | Embed organ-specific diagnostics in hospital radiology |
| Strategic Focus |
CNS & Neurology (End-to-end orchestration) |
Multi-Organ Diagnostics |
| AI Strategy |
Open Marketplace: Integrates proprietary + 3rd party gold-standards (FSL, FreeSurfer). |
Proprietary Ecosystem: Focused on the "Quibim Precision" suite of tools. |
| Flagship Focus | Reproducible neuroimaging workflows, site harmonization, and central review. | Tissue-agnostic radiomics, Digital Twin projects, and multi-omics. |
| Clinical Deployment Model | Fully managed SaaS; zero-footprint viewer; no local installation | PACS integration via QP-Link®; deployed directly into radiology workflows at hospitals |
| Regulatory Structure |
Platform-level 510(k) clearance, 21 CFR Part 11, GxP, HIPAA, and GDPR |
Product-by-product 510(k) clearance /CE mark per indication (QP-Prostate, QP-Brain) |
| Core Value Prop |
Reducing trial complexity via unified orchestration of any neuro-algorithm. |
Transforming images into data for personalized care in oncology. |
| Target User |
Sponsors and CROs running disease-modifying CNS trials; neuroscience academic centers. |
Oncology-focused Pharma, Radiologists, and Population Health Researchers. |
Both companies hold meaningful regulatory credentials, structured for different jobs.
QMENTA is compliant with 21 CFR Part 11, HIPAA, and other relevant regulations as the basis of security and privacy measures. Also, QMENTA receives FDA 510(k) clearance for the platform as a whole. It is covering the AI-powered imaging management and analysis environment as a single regulated medical product. For a sponsor, the practical benefit is that the data management, QC, audit trail, and reporting behind your endpoint sit inside a cleared, validated environment, reducing your own validation burden.
Quibim pursued a product-by-product clearance strategy, with each device cleared independently for its specific indication. QP-Prostate received FDA 510(k) clearance in March 2025 following a multi-reader, multi-case validation study. QP-Brain holds FDA 510(k) clearance, CE, and UKCA marks. QP-Liver holds CE and UKCA marks. The QP-Insights platform operates as the data management infrastructure layer beneath these cleared devices.
Regulatory distinction : QMENTA’s clearance covers the imaging management and analysis environment a trial endpoint runs in. Quibim’s clearances apply to specific point-of-care diagnostic devices. One is built to support a trial endpoint; the other to support a hospital diagnostic read.
QMENTA uses AI-driven automated sequence labeling, protocol checking, and real-time de-identification at upload to minimize administrative load on imaging sites. Quibim's QP-Link® solution connects to site PACS systems and pseudonymizes or anonymizes data before transmission to the Quibim cloud, enabling an automated workflow without direct patient-identifiable data leaving the site.
QMENTA includes a purpose-built Imaging workflow with query management, project management, and reporting built for trial operations. These tools are designed to support the operational cadence of a multi-site drug study including site training, imaging window tracking, query resolution, and final data delivery. Quibim's QP-Insights handles data management and biomarker analytics but does not include purpose-built trial EDC or imaging-specific query management.
Quibim has invested specifically in linking imaging data with electronic health records and multi-omics datasets within QP-Insights. For programs where imaging is one input into a broader precision medicine strategy, this integration is a genuine differentiator, for example, predicting immunotherapy response across imaging, genomic, and clinical variables. QMENTA's platform is imaging-centric and integrates with external EDC systems via open API, but does not offer native multi-omics linkage.
Quibim's cleared devices are designed to fit into radiology workflows at hospital sites, with QP-Link® connecting to existing PACS and returning results to the same system. For radiology departments that want AI-assisted diagnostics embedded in their standard workflow for prostate MRI or brain volumetrics, this deployment model is directly applicable. QMENTA's clinical care infrastructure runs entirely in the browser. No local installation or specialized workstations are required. This makes it straightforward to deploy across healthcare institutions without IT overhead.
Disease-modifying CNS trials live or die on a reproducible imaging endpoint: atrophy, lesion load, or tract integrity measured the same way at every site. QMENTA is built specifically to deliver that, with CNS-specific QC, harmonization, and validation against reference cohorts such as ADNI and PPMI. Quibim’s QP-Brain is a cleared hospital diagnostic device for brain volumetrics, not a multi-site trial endpoint solution. If your job is a regulated CNS trial, QMENTA is the partner designed for it. For programs focused on identifying imaging-based predictive biomarkers for treatment response, Quibim's precision medicine approach is more applicable.
QP-Insights, Quibim's data platform, is specifically designed to link imaging data with electronic health records and multi-omics datasets, positioning it as a tool for biomarker discovery programs where imaging is one dimension of a broader biological picture. QMENTA's platform is imaging-centric and focused on the imaging trial workflow. It integrates with external EDC systems and third-party data sources via open API.
No. They do different jobs. QP-Brain is a 510(k)-cleared device for quantifying brain atrophy and white matter hyperintensities at the point of care, valuable for hospital diagnostics and early disease assessment. A multi-site trial endpoint requires more: cross-site harmonization, automated sequence classification, trial QC, query management, and audit-ready reporting, backed by CNS-specific validation accumulated over years. That is what QMENTA delivers, and it is hard for a generalist or single-device tool to replicate quickly. QP-Brain can be used in a clinical trial as one of the trial endpoints used.
QMENTA provides over 50 validated AI biomarkers and algorithms, concentrated in CNS and oncology, available within a catalog and partner marketplace. These algorithms are pre-validated and can be integrated into trial workflows without custom development. Additionally, QMENTA offers a robust SDK, enabling research teams to develop, validate, and scale their own proprietary algorithms globally through QMENTA’s regulated infrastructure. Quibim's approach is organ-specific SaMD: each product is developed and cleared individually for its clinical application, with biopsy-verified or pathology-verified ground truth in products like QP-Prostate. Quibim also generates radiomics features for biomarker discovery research. Teams that want immediate access to a broad neuroimaging algorithm library will find QMENTA's catalog relevant; teams that want organ-specific AI tools with their own independent regulatory clearances may prefer Quibim's product model.
Quibim's cleared devices (e.g. QP-Prostate, QP-Brain, QP-Liver) are explicitly designed to integrate into radiology workflows at hospital sites via PACS connection. For radiology departments that want AI-assisted diagnostic support embedded in their standard workflow, Quibim's product design fits that context more directly. QMENTA's platform has 510(k) clearance for clinical care use. The platform deploys the AI algorithm and its analysis report together with its zero-footprint viewer.
Both platforms are pioneers in the medical imaging space, yet they serve different operational roles: QMENTA as the orchestrator of the imaging workflow, and Quibim as the specialized engine for radiomic discovery.
| Choose QMENTA If... | Choose Quibim If... |
|---|---|
|
You are running a regulated multi-site imaging clinical trial and need a single end-to-end infrastructure for data management, QC, central review, and regulatory reporting. |
You need organ-specific AI diagnostic tools (prostate, brain, liver) integrated into hospital radiology workflows via PACS. |
|
You want a partner whose data management, QC, and reporting sit inside a cleared, validated environment, reducing your own validation burden. |
You need cleared SaMD devices with independent indication-specific regulatory clearances for clinical use. |
|
CNS and neurodegeneration are your therapeutic focus and you need CNS-specific QC, automated sequence classification, and validated endpoints. |
Your program focuses on immunotherapy response prediction, patient stratification, or multi-omics biomarker discovery where imaging is one dimension of a broader biological dataset |
|
You need a purpose-built Imaging workflow with query management, audit trails, and reporting for trial operations. |
You need native integration of imaging data with EHR records and multi-omics for precision medicine analytics. |
|
You want a fully managed SaaS solution with zero-footprint deployment at imaging sites and no local IT requirements. |
You want AI-powered radiology tools that plug into existing PACS infrastructure and return structured outputs to the same clinical system. |
|
You want access to a broad catalog of pre-validated AI imaging biomarkers across multiple CNS and oncology indications. |
You are building organ-level digital twin models or running large-scale real-world evidence programs across heterogeneous imaging datasets. |
Planning a CNS clinical trial? See how QMENTA delivers a reproducible, submission-ready imaging endpoint across every site: Schedule a 30-minute meeting with QMENTA's imaging specialists.